Table 1.
Drugs employed in HNSCC.
| Drug | Category | Status |
|---|---|---|
| Cetuximab | Targeted Therapy (anti-EGFR) |
APPROVED |
| Panitumumab | Targeted Therapy (anti-EGFR) |
experimental |
| Losatuxizumab vedotin | Targeted Therapy (anti-EGFR) |
experimental |
| Erlotinib | Targeted Therapy (anti-EGFR) |
experimental |
| Gefitinib | Targeted Therapy (anti-EGFR) |
experimental |
| Afatinib | Targeted Therapy (anti-EGFR) |
experimental |
| Nivolumab | Immunotherapy (anti PD-1) |
APPROVED |
| Ipilimumab | Immunotherapy (anti CTLA-4) |
experimental |
| Pembrolizumab | Immunotherapy (anti PD-1) |
APPROVED |
| Atezolizumab | Immunotherapy (anti PD-L1) |
experimental |
| Monalizumab | Immunotherapy (anti-NKG2) |
experimental |
| Palbociclib | Targeted Therapy (anti-CDK 4/6) |
experimental |
| Trametinib | Targeted Therapy (anti-Mek) |
experimental |
| PARP-inhibitors | Targeted Therapy (anti-PARP) |
experimental |
| AZD6738 | Targeted Therapy (anti-ATR) |
experimental |
| Prexasertib | Targeted Therapy (anti-CHK1/2) |
experimental |
| Adavosertib | Targeted Therapy (anti-WEE1) |
experimental |
| Buparlisib | Targeted Therapy (anti-PI3K) |
experimental |
| Epacadostat | Immunotherapy (anti-IDO1) |
experimental |
| GSK3359609 | Immunotherapy (ICOS agonist) |
experimental |